HLA alleles modulate EBV viral load in multiple sclerosis by S. Agostini et al.
Agostini et al. J Transl Med  (2018) 16:80  
https://doi.org/10.1186/s12967-018-1450-6
RESEARCH
HLA alleles modulate EBV viral load 
in multiple sclerosis
Simone Agostini1* , Roberta Mancuso1, Franca R. Guerini1, Sandra D’Alfonso2, Cristina Agliardi1, 
Ambra Hernis1, Milena Zanzottera1, Nadia Barizzone2, Maurizio A. Leone3, Domenico Caputo1, Marco Rovaris1 
and Mario Clerici1,4
Abstract 
Background: The etiopathology of multiple sclerosis (MS) is believed to include genetic and environmental factors. 
Human leukocyte antigen (HLA) alleles, in particular,  are associated with disease susceptibility, whereas Epstein Barr 
Virus (EBV) infection has long been suspected to play a role in disease pathogenesis. The aim of the present study is to 
evaluate correlations between HLA alleles and EBV infection in MS.
Methods: HLA alleles, EBV viral load (VL) and serum anti-EBV antibody titers were evaluated in EBV-seropositive MS 
patients (N = 117) and age- and sex-matched healthy controls (HC; N = 89).
Results: Significantly higher DNA viral loads (p = 0.048) and EBNA-1 antibody titer (p = 0.0004) were seen in MS com-
pared to HC. EBV VL was higher in HLA-B*07+ (p = 0.02) and HLA-DRB1*15+ (p = 0.02) MS patients, whereas it was 
lower in HLA-A*02+ (p = 0.04) subjects. EBV VL was highest in HLA-A*02−/B*07+/DRB1*15+ patients and lowest in 
HLA-A*A02+/B*07−/DRB1*15− individuals (p < 0.0001). HLA-B*07 resulted the most associated allele to EBV VL after 
multiple regression analysis considering altogether the three alleles, (p = 0.0001). No differences were observed in 
anti-EBV antibody titers in relationship with HLA distribution.
Conclusions: Host HLA-B*07 allele influence EBV VL in MS. As HLA-class I molecules present antigens to T lympho-
cytes and initiate immune response against viruses, these results could support a role for EBV in MS.
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Background
Multiple sclerosis (MS), a chronic inflammatory disease 
of the central nervous system (CNS), is the most common 
cause of neurological disability in adults, and it affects 
over 2.5 million people worldwide [1]. The etiopathogen-
esis of the disease is still unclear and is believed to include 
both environmental and genetic factors, whose interplay 
leads to chronic activation of immune cells and neuronal 
damage. The major human leukocyte antigens (HLA) 
locus (6p21.3), in particular, was identified as the chro-
mosomal region most strongly linked to MS [2], and a 
number of epidemiological studies identified HLA alleles 
that correlate with an increased risk of developing MS 
and that can influence disease progression in patients. 
Notably, the realization that different HLA alleles play a 
role in MS led to the understanding that this disease is, 
above all, an antigen-specific autoimmune disease [3]. 
To date, HLA-DRB1*15 is the strongest risk factor for 
the development of MS [4]. HLA-DRB1*15 is neverthe-
less not the only HLA allele related to MS: HLA-B*07+ 
patients are characterized by higher disease burdens and 
by a more evident degree of brain atrophy [5]. The pres-
ence of the HLA-A*02 allele, on the other hand, seems to 
be a protective factor against MS [6] and, in patients with 
the disease, it results in a more favorable clinical course, 
with a slower progression and a lower disease burden [7].
Amongst environmental factors, chronic viral infec-
tions, including those supported by Epstein Barr virus 
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MS [8]. EBV (also called human herpesvirus 4, HHV-
4) is a ubiquitous human virus with a double stranded 
DNA genome (172 kbp long) wrapped in a protein cap-
sid belonging to the Herpesviridae family, Gamma-
herpesvirinae subfamily, Lymphocryptovirus genus [9]. 
The virus is a worldwide pathogen and is persistently 
harbored by almost all adults regardless of health or 
geographic location. In western countries, with high 
standard of living, primary EBV infection occurs com-
monly in adolescence, and might cause infectious mono-
nucleosis (IM) in a minority of cases. EBV replicates in 
oropharyngeal epithelial cells during primary disease and 
subsequently establishes a latent infection in circulating 
B lymphocytes.
IM and elevated titers of antibodies against EBV 
nuclear antigens (EBNA) have been associated to an 
increased risk to develop MS and, on the other hand, lack 
of EBV infection correlates with a lower risk to develop 
the disease [8]. Other epidemiologic results suggest-
ing a role for EBV in the pathogenesis of MS include the 
observations that EBV-infected B cells and plasma cells 
accumulate in the brain of MS patients [10] and a strong 
EBV specific cell-mediated immune responses are seen in 
these patients [11, 12].
Moreover, evidences of EBV DNA or transcripts in 
brain or cerebrospinal fluid of MS individuals remains 
controversial [13], as reported by some papers [10, 14], 
but not confirmed by other authors [15–17].
Confliting results are reported on possible correla-
tions between HLA alleles, EBV infection, and MS [18, 
19]. Thus, an interaction between HLA-class I alleles and 
reactivity to EBV-related epitopes was recently shown, 
suggesting that the mechanism through which HLA 
genes influence the risk of developing MS may involve 
EBV-specific immune responses [18, 20]. Other data 
showed that HLA-B*7 allele is associated with increased 
EBV-specific Ab titers, higher disability scores, and a 
more compromised MRI pattern in MS patients [21]. We 
verified if correlations could be established between pro-
tective/risk HLA-class I alleles and EBV-specific param-
eters in MS; results suggest that this is indeed the case.
Methods
Study population and specimens
A total of 206 individuals were enrolled in the study: 117 
of them (mean age: 44.7 ± 12.6 years) were patients with 
a diagnosis of MS according to revised McDonald crite-
ria [22]; these patients are followed by the Multiple Scle-
rosis Unit of the Don C. Gnocchi Foundation, IRCCS S. 
Maria Nascente in Milan, Italy, and by the MS Centers of 
the PROGEMUS Consortium, coordinated at the Univer-
sity of Piemonte Orientale. The remaining 89 individuals 
(mean age: 44.8 ± 10.8 years) were age- and sex-matched 
healthy controls (HC), who donate blood at the same 
institutions. HC and MS patients were selected in order 
to obtain comparable distribution of HLA-B*07, -A*02 
and -DRB1*15 frequency.
All individuals were EBV-seropositive. The study con-
formed to the ethical principles of the Declaration of 
Helsinki; all subjects gave informed and written consent 
according to a protocol approved by the local ethics com-
mittee of the centers.
Whole blood and serum samples were collected from 
all the individuals enrolled in the study. Whole blood was 
utilized for DNA extraction, whereas serum samples, 
obtained by centrifugation for 10 min at 1800g at room 
temperature, were aliquoted into sterile cryovials and 
stored at − 20 °C.
DNA extraction
Genomic DNA was extracted from whole blood using 
standard phenol/chloroform procedure. DNA amount 
for each sample was determined by measuring the opti-
cal density at 260  nm wavelengths. DNA samples were 
stored at − 20 °C until use.
HLA genotyping
The molecular genotyping of HLA-class I (HLA-A: 18 
alleles and HLA-B: 38 alleles) and HLA-class II polymor-
phisms (HLA-DRB1: 18 alleles) was performed as previ-
ously described [23, 24].
ELISA analysis
EBV seropositivity was measured in serum using com-
mercial enzyme immunoassays (BEIA EBV EBNA-1 IgG 
Quant, Technogenetics, Milan, Italy, and EBV viral capsid 
antigen (VCA) IgG ELISA, IBL International, Hamburg, 
Germany), according to the manufacturer instructions.
EBNA-1-specific Ab (U/ml) were considered positive 
if > 180 U/ml, or negative if < 150 U/ml. Samples in grey 
zone (between 150 and 180  U/ml) were re-tested using 
the same immunoassay, and if repeatedly resulted in the 
grey zone, they was excluded from the analysis.
VCA-specific Ab (U/ml) were considered positive if 
> 22 U/ml, or negative if < 8 U/ml. Samples in grey zone 
(between 8 and 22 U/ml) were re-tested using the same 
immunoassay, and if repeatedly resulted in the grey zone, 
they was excluded from the analysis.
Cytomegalovirus (CMV) seropositivity was measured 
in serum using commercial enzyme immunoassay (CMV 
IgG ELISA, IBL International), according to the manufac-
turer instructions.
CMV IgG-specific Ab (U/ml) were considered positive 
if > 12 U/ml, or negative if < 8 U/ml. Samples in grey zone 
(between 8 and 12 U/ml) were re-tested using the same 
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immunoassay, and if repeatedly resulted in the grey zone, 
they was excluded from the analysis.
EBV and CMV DNA viral load
500  ng of genomic DNA was used as the template for 
quantitative evaluation by quantitative PCR (qPCR) using 
the ABI Prism 7000 sequence detection system (Applied 
Biosystems, Foster City, CA, US), and following a previ-
ously described protocol [25]. For EBV, the sequences of 
primers and probes were designed by Applied Biosystems 
on EBNA-LP region, whereas for CMV, primers CMVF 
(5′-CGC TCA CAT GCA AGA GTT AAT CTT T), CMVR 
(5′AAC TCG GTA AGT CTG TTG ACA TGT ATG) and 
probe CMVP (FAM-CTC TAT CTG ACA TAC ACA AGT 
AAA TCC ACG TCCCA-TAMRA) were selected from the 
UL123 gene using the Primer Express version 2.0.0 soft-
ware. The EBNA-LP region is rich of variable copy num-
bers of a repeat domain: although the primers/probes 
were optimized by a commercial company, an effect on 
the results can’t be categorically exclude. EBV and CMV 
viral load was measured on a single occasion in each 
patient; each sample was tested in triplicate. Negative 
controls, as well as serial dilutions (from  104 to 10 cop-
ies/μl for both EBV and CMV) of commercially available 
viral genomes (Advanced Biotechnologies Inc., Colum-
bia, MD, USA), were included in each run. For both EBV 
and CMV the detection limit of this specific qPCR assay 
was 2.1 copies/μg DNA.
Statistical analysis
Normally distributed data were summarized as mean 
and standard deviation (SD), or standard error mean 
(SEM), and comparison among groups were analyzed by 
ANOVA test and Student t test. Not-normally distributed 
data were summarized as median and interquartile range 
(IQR: 25th and 75th percentile), and comparisons were 
analyzed by Kruskal–Wallis test and Mann–Whitney U 
test, as appropriate. Multiple regression analysis was per-
formed to verify the possible association between viral 
data and genetic parameters. Qualitative data were com-
pared using Fisher’s exact test.
Results
Clinical characterization of study subjects
Clinical characteristics of the individuals enrolled in 
the study are shown in Table  1. Demographic analysis 
showed that age and sex were not different when MS 
patients and HC were compared. Among MS patients, 77 
were affected by relapsing–remitting disease (RR-MS) in 
a phase of disease stability, whereas 40 had a diagnosis of 
progressive MS (P-MS, 15 with primary form and 25 with 
secondary form). As per definition, the expanded dis-
ability status scale (EDSS) score was significantly higher 
in P-MS (6.1 ± 2.1) than in RR-MS (2.9 ± 1.6, p < 0.0001). 
Within the MS group of patients the age at disease onset 
was significantly lower in RR-MS compared to P-MS 
(p = 0.04), but the disease duration was comparable (data 
not shown).
EBV seropositivity and viral load
All the 206 individuals included in the study were IgG 
EBNA-1 and VCA seropositive. The EBNA-1 anti-
body titer was significantly higher in MS (1009.23; 
782.79–1383.37 U/ml) compared to HC (782.55; 627.82–
910.95 U/ml; p < 0.0001). This difference remained signif-
icant when MS patients were split in RR-MS (p = 0.0008 
vs. HC) and in P-MS (p = 0.03 vs. HC). IgG EBNA-1 Ab 
titers were comparable in RR-MS and P-MS patients 
(Table 2).
The VCA antibody titer was significantly higher in MS 
(969.07; 511.62–1340.41 U/ml) compared to HC (375.54; 
144.77–625.19  U/ml; p = 0.02). When MS patients were 
split in RR-MS and in P-MS, this difference remained sig-
nificant between RR-MS and HC (p = 0.01), whereas no 
Table 1 Demographic, clinical and genetic characteristics of the individuals enrolled in the study
Data are expressed as mean ± standard deviation
EDSS Expanded Disability Status Scale
* p < 0.0001 vs. RR-MS






N 89 117 77 40
Gender (M:F) 43:46 48:69 32:45 16:24
Age (years) 44.8 ± 10.8 44.7 ± 12.6 42.1 ± 9.5 50.8 ± 10.2
EDSS – 3.8 ± 2.2 2.9 ± 1.6 6.1 ± 2.1*
HLA-A*02 carriers (%) 64 62 66 60
HLA-B*07 carriers (%) 69 60 61 57
HLA-DRB1*15 carriers (%) 68 64 63 68
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significant differences were observed between P-MS and 
HC, and between RR-MS and P-MS (Table 2).
EBV DNA was significantly more frequently detected 
in MS patients (54/117; 46.1%) compared to HC (25/89; 
28.1%) (p = 0.009). Moreover, although the median is 
the same in MS and HC group (2.0 copies/μg), the over-
all EBV DNA viral load is significantly increased in MS 
patients (IQR: 2.00–37.50 copies/μg) than HC (IQR: 
2.00–2.36 copies/μg) (p = 0.006) (Fig. 1).
Finally, no differences were detected when either EBV 
DNA or viral loads were compared between RR-MS (EBV 
DNA positivity: 48%; EBV viral load: 2.0; 2.0–39.3 copies/
μg) and P-MS (EBV DNA positivity: 43%; EBV viral load: 
2.0; 2.0–28.9 copies/μg) patients. As previously indicated, 
all the individuals enrolled in the study were EBV sero-
positive; some of them, nevertheless, had an undetectable 
EBV viral load. An arbitrary value < 2 copies/μg (i.e. the 
limit detection of the assay) was assigned to these sam-
ples for the analysis of association with HLA genotyping. 
No correlation was observed between EBV viral load and 
EBV or VCA Ab titers, either considering the enrolled 
subject altogether, either considering the enrolled indi-
viduals as a group or splitting them in MS and HC (see 
Additional file 1: Figure S1).
CMV seropositivity and viral load
The 70.2% of MS and the 64.3% of HC were CMV IgG 
seropositive. The antibody titer was similar in the two 
groups (MS: 83.40; 46.33–119.56 U/ml; HC: 58.40; 38.15–
84.47 U/ml) (Table 2), and no differences were observed 
also splitting the patients in RR-MS and P-MS. The CMV 
viral load was not detectable in blood in all the enrolled 
subjects but in one healthy control (VL: 65.75 copies/μg).
HLA genotyping and EBV
HLA-A, -B, and -DRB1 genotyping was performed in all 
the enrolled subjects and genetic patterns were evaluated 
in relationship with EBV parameters. The HLA frequen-
cies are summarized in Table  1. Results showed that a 
significantly higher EBV viral load could be detected in 
MS subjects carrying the HLA-B*07 allele (non-pro-
tective allele) (HLA-B*07+) (N = 47/117) (37.54; 2.0–
74.25  copies/µg) compared to those not carrying this 
allele (HLA-B*07−) (N = 70/117) (2.0; 2.0–2.0  copies/
μg; p < 0.0001) (Fig.  2a). Similarly, MS patients carrying 
the HLA-DRB1*15 allele (risk allele) (HLA-DRB1*15+) 
(N = 42/117) had higher EBV viral load (11.7; 2.0–58.3 
copies/µg) than those not carrying this allele (HLA-
DRB1*15−) (N = 75/117) (2.0; 2.0–21.1  copies/µg) 
(Fig. 3a) (p = 0.02).
Conversely, a significantly lower EBV viral load was 
observed in MS patients expressing the HLA-A*02 anti-
gen (HLA-A*02+) (N = 44/117) (2.0; 2.0–2.1  copies/
µg), which is suggested to be a protective factor in MS, 
compared to those without the allele (HLA-A*02−) 
(N = 73/117) (2.9; 2.00–37.65  copies/µg; p = 0.01) 
(Fig.  4a). EBV viral load was next evaluated in MS 
patients in relationship with the different distribu-
tion pattern of HLA-A*02, -B*07 and -DRB1*15 alleles. 
Table 2 EBV and CMV seroprevalence and antibodies titers in MS patients and controls
Data are expressed as medians and (interquartile range)
EBV Epstein-Barr Virus, CMV cytomegalovirus, EBNA1 EBV nuclear antigen 1, VCA viral capsid antigen, IgG immunoglobulin G, VL viral load
* p < 0.0001 vs. HC
** p < 0.05 vs. HC
Healthy controls (HC) Multiple sclerosis patients (MS) Relapsing–remitting MS 
patients (RR-MS)
Progressive MS patients (P-MS)
EBV seroprevalence (%) 100 100 100 100
EBNA-1 IgG (U/ml) 782.55 (627.82–910.95) 1009.23* (782.79–1383.37) 1139.00* (782.70–1452.15) 937.29** (828.82–1191.21)
VCA Ab (U/ml) 375.54 (144.77–625.19) 969.07** (511.62–1340.41) 1146.45** (560.95–1407.95) 885.15 (277.02–1050.24)
CMV seroprevalence (%) 64.3 70.2 69.7 71.2
























Fig. 1 EBV viral load in blood of multiple sclerosis patients and 
healthy controls
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b
Fig. 4 EBV viral load in blood of multiple sclerosis patients (a) and healthy controls (b) carrying HLA-A*02. Black dots represent subjects carrying 
HLA-B*07 allele
Page 6 of 9Agostini et al. J Transl Med  (2018) 16:80 
Results showed that the highest EBV viral load (37.5; 
2.1–72.1 copies/µg) was detected in HLA-B*07+/HLA-
DRB1*15+/HLA-A*02− (least favorable HLA combina-
tion) patients (N = 23); conversely, the 25 HLA-B*07−/
HLA-DRB1*15−/HLA-A*A02+ patients were character-
ized by the lowest EBV viral load (2.0; 2.0–2.0 copies/µg) 
(p < 0.0001) (Fig. 5a).
Moreover, a multiple regression analysis where EBV 
viral load was computed as dependent variable and HLA-
B*07, -A*02 and –DRB1*15 alleles as independent vari-
ables, confirmed only the association of HLA-B*07 with 
high EBV viral load (p = 0.0001). These data suggest that 
the risk effects of the HLA-B*07 allele are stronger than 
the “protective” ones attributed to the HLA-A*02 allele 
and than the “risk” ones attributed to the HLA-DRB1*15 
allele. Notably, the relationship between HLA alleles and 
viral parameters was exclusively seen in MS patient as no 
such effects could be observed in the 89 HC (Figs. 2, 3, 4 
and 5b).
Splitting MS patients between RR-MS and P-MS, 
results regarding the association between EBV viral load 
was significantly higher in RR-MS expressing the HLA-
B*07 antigen (37.5; 2.1–74.0 copies/µg) than those not 
carrying this allele (2.0; 2.0–4.7 copies/µg; p < 0.0001). 
EBV viral load was significantly increased as well in P-MS 
carrying -B*07 (37.5; 15.6–97.79 copies/µg) compared 
to P-MS patients who did not carry this allele (2.0; 2.0–
2.0 copies/µg; p < 0.0001). Regarding the others alleles, 
results were confirmed for DRB1*15 in P-MS patients 
(p = 0.009) (Fig.  6). Notably, comparable EBV viral load 
characterized RR-MS and P-MS expressing the same 
HLA molecules.
Finally, no relationships were found between HLA 
distribution and EBV-specific antibody titers, either 
considering the enrolled individuals as a group or split-
ting them in MS and HC.
Discussion
The etiology of MS is still unknown, but it is widely 
accepted that interactions between environmental and 
genetic factors shape the susceptibility to this multifac-
torial disease. Thus, whereas the correlation between 
certain HLA alleles and disease susceptibility has been 
definitely established, the possible association between 
EBV infection and MS has been repeatedly suggested but 
is still in need of convincing and definitive conclusions.
Herein we initially analyzed EBV infection parameters 
in a MS study population; our results confirmed previous 
data indicating that higher anti-EBNA-1 IgG serum titers 
are present in MS patients compared to HC [8, 26]. We 
also observed that, in MS patients compared to controls: 
(1) EBV DNA in blood is more frequently detected, and 
(2) EBV viral loads are significantly increased, although 
these viral loads are not comparable to those seen in 
EBV-associated malignancies [27]. These data con-
firm previously published results [28, 29], even if not all 
authors confirm such findings [30, 31], and could be the 
consequence of increased rates of EBV replication, more 
frequent reactivations, or of higher frequencies of circu-
lating EBV-infected B lymphocytes [32]. However, it is 
important to note that, because in our experiments DNA 
was extracted from whole blood, viral DNA originating 
from B cells could not be discriminated from that origi-
nating from virions.
No relations were observed between EBV-specific 
antibody titers and EBV viral load in the study popula-
tion. These results are partially in agreement with recent 





















































Fig. 5 EBV viral load in blood of multiple sclerosis patients (a) and of healthy controls (b) in relationship with the co-segregation of HLA-A*02, -B*07 
and -DRB1*15 alleles
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do correlate with EBV viral load, EBNA-1-specific Ab do 
not [33]; analyses on wider cohorts of individuals will be 
needed to clarify this aspect.
Having covered the virological side, we next analyzed 
whether polymorphisms in the HLA region known to 
modulate MS susceptibility [34] and its progression 
could associate with virologic parameters. Several lines 
of evidence indicate the presence of possible interactions 
between EBV infection-associated parameters, usually 
EBNA-1 antibody titers, and HLA profiles in MS; these 
evidences are nevertheless not unequivocal [18–21, 35, 
36]. Whereas in our cohort we did not observe any cor-
relations between anti-EBV antibody titers and HLA 
antigens, possibly because of the small number of indi-
viduals analyzed, clear correlations emerged between 
HLA alleles and EBV viral loads. Thus, results showed 
that patients carrying the MS risk allele B*07 (HLA-
B*07+) in the presence of the risk allele DRB1*15 and in 
the absence of the protective allele A*02 (HLA-B*07+/
DRB1*15+/A*02−) were characterized by the presence 
of the highest EBV viral loads. These findings were con-
firmed by the observation that the lowest EBV viral loads 
were seen in MS patients showing the opposite HLA pro-
file (HLA-B*07−/DRB1*15−/A*02+). The same trend 
remained when HLA-B*07, DRB1*15 and HLA-A*02 
alleles were analyzed singularly. To note, analyzing the 
effects of HLA alleles altogether by multiple regression 
analysis, HLA-B*07 allele appears to have the strongest 
role on EBV DNA viral load. It is noteworthy that HLA-
B*07 belongs to the same HLA haplotype carrying the 
HLA-DRB1*15 allele, whose association with MS suscep-
tibility is well-established. Recently, a role of B*07 in EBV 
infection in MS patients has been proposed [12]. It is also 
important to observe that these correlations disappeared 
when the analyses were performed in healthy controls.
Conclusions
Merging the virologic and the genetic results presented 
herein allows the speculation that the increased blood 
viral loads seen in our patients are the consequence of 
a suboptimal control of EBV replication/reactivation 
by HLA-B*07+ restricted  CD8+ T cell. Notably, HLA-
B*07 antigen was recently shown to only weakly pre-
sent viral epitopes to cytotoxic T lymphocytes [11]. This 
would allow more frequent EBV lytic replication/reac-
tivation and the infection of an ampler pool of naïve B 
lymphocytes.
The suboptimal control of EBV replication/reactiva-
tion observed in HLA-B*07+ MS subjects may have had 
an impact on disease severity, but interestingly, no dif-
ferences in EBV viral load were observed between HLA-
B*07+ restricted RR- and P-MS patients. Finally, it could 
be expected that the frequency and/or the potency of 
EBV-specific cytotoxic T cell would be different in MS 
patients expressing (or lacking) the different HLA alleles 

















































































































































HLA-A*02- HLA-A*02+ HLA-B*07- HLA-B*07+ HLA-DRB1*15- HLA-DRB1*15+ 
a 
b 
Fig. 6 EBV viral load in blood of RR-MS (a) and P-MS (b) carrying HLA-A*02, -B*07 and -DRB1*15 alleles
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and controls selected according to their HLA profiles to 
verify this hypothesis. Interestingly, these results are in 
line with several analyses performed in other diseases in 
which the etiologic role of EBV is suspected, or has been 
definitely confirmed. Thus, the presence of the HLA-
A*02 allele was shown to be protective in nasopharyngeal 
carcinoma and in Hodgkin’s lymphomas [37, 38]. Taken 
together results herein reinforce the hypothesis that the 
role of HLA-class I antigens in the pathogenesis of MS 
could be at least partially mediated by their ability to con-
trol EBV infection and persistence.
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